A phase 3 trial of a new ovarian cancer drug has shown promising results, Associate Professor Gary Richardson from Monash University told the Clinical Oncological Society of Australia Annual Scientific Meeting this week.
AMG 386, an investigational peptide-Fc fusion protein, neutralizes the interaction between the Tie2 receptor and angiopoietin-1 and -2, in patients with advanced ovarian cancer.
Researchers randomised 161 patients to one of three arms: paclitaxel 80mg/m2 combined with either AMG 386 10mg/kg or 3mg/kg or placebo.
Patients in the high-dose arm had a median profession free survival of 7.2 months compared to 5.7 in the low dose group and 4.6 months in the placebo group.
The study also showed that AMG 386 is is well tolerated and reduces...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.